Comparison of reperfusion, clinical outcome, and mortality in large randomized controlled trials and in our study
| REVASCAT (%) | SWIFT PRIME (%) | EXTEND-IA (%) | ESCAPE (%) | MR CLEAN (%) | Our study thrombectomy cases (n=8) (%) | |
| TICI 2b–3 | 66 | 88 | 86 | 72 | 59 | 12.5 |
| mRS (0–2) | 44 | 60 | 71 | 53 | 33 | 12.5 |
| Mortality | 18 | 9 | 9 | 10 | 19 | 62.5 |
ESCAPE, Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke; EXTEND-IA, Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial; MR CLEAN, Multicenter Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands; mRS, modified Rankin Scale; REVASCAT; Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours; SWIFT PRIME, Solitaire With the Intention For Thrombectomy as Primary Endovascular Treatment; TICI, Thrombolysis in Cerebral Infarction.